Promoter Genotyping and mRNA Expression - Based Analysis of the PTGDR Gene in Allergy.

BACKGROUND AND OBJECTIVE: Prostaglandin D2 receptors are acquiring a relevant role as potential therapeutic targets in allergy. PTGDR has been described as a candidate gene in allergic disease, although functional studies on this gene are lacking. Objective: The objective of this case-control study was to investigate the potential role of PTGDR in allergy. METHODS: The study population comprised 195 allergic patients and 112 healthy controls. The PTGDR promoter polymorphisms -1289G>A, -1122T>C, -881C>T, -834C>T, -613C>T, -549T>C, -441C>T, -197T>C, and -95G>T were amplified by polymerase chain reaction (PCR) and sequenced. PTGDR expression levels were analyzed using quantitative PCR and normalized to GAPDH and TBP mRNA levels. All procedures were performed following the Minimum Information for Publication of Quantitative Real-Time PCR Experiment guidelines. RESULTS: PTGDR expression levels were significantly higher in allergic patients than in controls (P<.001). Receiver operating characteristic analysis for expression of PTGDR showed a sensitivity of 81.4% compared with 67% for IgE levels. In addition, differences in the genotypic distribution of the polymorphisms -1289G>A and -1122T>C were found in allergic patients (P=.009). CONCLUSIONS: The results indicate that PTGDR overexpression is associated with allergy. The polymorphisms -1289G>A and -1122T>C partly explain the variation in expression we observed. PTGDR expression could have a potential role as a biomarker and pharmacogenetic factor in allergy.

Promoter genotyping and mRNA expression - based analysis of the PTGDR gene in allergy

BACKGROUND: Prostaglandin D2 receptors are acquiring a relevant role as potential therapeutic targets in allergy. PTGDR has been described as a candidate gene in allergic disease, although functional studies on this gene are lacking. OBJECTIVE: The objective of this case-control study was to investigate the potential role of PTGDR in allergy. METHODS: The study population comprised 195 allergic patients and 112 healthy controls. The PTGDR promoter polymorphisms -1289G>A, -1122T>C, -881C>T, -834C>T, -613C>T, -549T>C, -441C>T, -197T>C, and -95G>T were amplified by polymerase chain reaction (PCR) and sequenced. PTGDR expression levels were analyzed using quantitative PCR and normalized to GAPDH and TBP mRNA levels. All procedures were performed following the Minimum Information for Publication of Quantitative Real-Time PCR Experiment guidelines. RESULTS: PTGDR expression levels were significantly higher in allergic patients than in controls (P<.001). Receiver operating characteristic analysis for expression of PTGDR showed a sensitivity of 81.4% compared with 67% for IgE levels. In addition, differences in the genotypic distribution of the polymorphisms -1289G>A and -1122T>C were found in allergic patients (P=.009). CONCLUSIONS: The results indicate that PTGDR overexpression is associated with allergy. The polymorphisms -1289G>A and -1122T>C partly explain the variation in expression we observed. PTGDR expression could have a potential role as a biomarker and pharmacogenetic factor in allergy

ANTECEDENTES: Los receptores de la prostaglandina D2 están adquiriendo un papel relevante como posibles dianas terapéuticas en la alergia. El gen PTGDR ha sido descrito como un gen candidato en una enfermedad alérgica, sin embargo, faltan estudios funcionales sobre este gen. OBJETIVO: El objetivo de este estudio de casos y controles fue analizar el posible papel del gen PTGDR en la alergia. MÉTODOS: Se incluyeron 195 pacientes alérgicos y 112 controles sanos. Un fragmento de la región promotora de PTGDR que comprendía las posiciones polimórficas -1289G> A, -1122T>C, -881C>T, -834C>T, -613C>T, -549T>C, -441C>T, -197T>C y -95G>T fue amplificado mediante la reacción en cadena de la polimerasa y secuenciado. Los niveles de expresión de PTGDR se analizaron mediante q-PCR y se normalizaron a los niveles de ARNm de GAPDH y TBP. Todos los procedimientos se realizaron siguiendo la guía MIQE. RESULTADOS: Los niveles de expresión de PTGDR fueron significativamente superiores en los pacientes alérgicos que en los controles (p < 0,001). El análisis ROC para la expresión de PTGDR mostró una sensibilidad del 81,4% en comparación con el 67% para los niveles de IgE. Además, se encontraron diferencias en la distribución genotípica de los polimorfismos -1289G>A y -1122T>C en pacientes alérgicos (p = 0,009). CONCLUSIONES: Los resultados indican que la sobreexpresión de PTGDR se asocia con la alergia. Además, los polimorfismos -1289G>A y -1122T>C contribuyen a explicar parte de la variación de expresión observada. La expresión de PTGDR podría tener un papel potencial como biomarcador y factor farmacogenético en la alergia